It's important that women understand if they're sexually active, there's a chance they won't receive full benefit from the vaccine.
--Dr. Laura Koutsky, epidemiologist at the University of Washington
I get asked this question a lot by women who are already sexually active including some who have had abnormal Pap smears as a result of infections by the human papillomavirus (HPV). HPV infections cause virtually all cervical cancer, and bad actor HPV types 16 and 18 are responsible for 70% of these malignancies. The Gardasil vaccine (and the not yet approved Cervarix vaccine) is highly effective at inducing immunity against these carcinogenic viruses; in fact, this vaccine is the first one to specifically designed to prevent cancer caused by a virus.
Dr. Koutsky and company (an enormous panel of clinical investigators) published the results of their FUTURE II trial, aka Females United to Unilaterally Reduce Endo/Ectocervical Disease, in a May, 2007 edition of the NEJM(1). While the vaccine prevented 98% of cervical lesions--precancerous and malignant--in subjects who tested negative for exposure to HPV types 16 and 18 at the time of entry into the study, it was only 44% protective in women previously infected with these cancer-causing viruses.
The ideal population, therefore, that will benefit from this vaccine is those girls/women not yet exposed to the virus. The CDC's Advisory Committee on Immunization Practices has recommended without reservation that girls 11 and 12 years of age receive this shot.
_____
(1)The FUTURE II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. NEJM,Volume 356:1915-1927, May 10 2007.
ca-pub-1793295148737117
|
--Dr. Laura Koutsky, epidemiologist at the University of Washington
I get asked this question a lot by women who are already sexually active including some who have had abnormal Pap smears as a result of infections by the human papillomavirus (HPV). HPV infections cause virtually all cervical cancer, and bad actor HPV types 16 and 18 are responsible for 70% of these malignancies. The Gardasil vaccine (and the not yet approved Cervarix vaccine) is highly effective at inducing immunity against these carcinogenic viruses; in fact, this vaccine is the first one to specifically designed to prevent cancer caused by a virus.
Dr. Koutsky and company (an enormous panel of clinical investigators) published the results of their FUTURE II trial, aka Females United to Unilaterally Reduce Endo/Ectocervical Disease, in a May, 2007 edition of the NEJM(1). While the vaccine prevented 98% of cervical lesions--precancerous and malignant--in subjects who tested negative for exposure to HPV types 16 and 18 at the time of entry into the study, it was only 44% protective in women previously infected with these cancer-causing viruses.
The ideal population, therefore, that will benefit from this vaccine is those girls/women not yet exposed to the virus. The CDC's Advisory Committee on Immunization Practices has recommended without reservation that girls 11 and 12 years of age receive this shot.
_____
(1)The FUTURE II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. NEJM,Volume 356:1915-1927, May 10 2007.